Summary:
A Phase 3, Randomized, Placebo-Controlled, Observer-Blinded Trial to Evaluate the Safety of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) in Healthy Children 5 Through 17 Years of Age
Criteria:- Be 5-17 years old
- Be in general good health
- Have no previous vaccine for Lyme Disease
- Additional criteria apply
Qualified Participants May Receive:
- Study-related care at no cost
- Compensation up to $800 for time and trial-related travel expenses